Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear.
Sanofi and Novo Nordisk this morning have put their venture arms to work. The two joined up with two venture firms to back a $49 million round for a fledgling startup,... Read more »
ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge of its most substantial clinical test to date, the company has... Read more »
The latest evidence of the progress of targeted cancer drugs came this morning in the form of a $400 million check. That’s what Bayer will pay, up front, to Loxo Oncology,... Read more »
Call it a week of second chances. Multiple biotechs breathed new life into drugs sorely in need of it. Sage Therapeutics proved a drug that had failed a trial a rare... Read more »
There may be a new treatment on the horizon for postpartum depression, an often severe form of depression that affects women after childbirth. Sage Therapeutics reported this morning that an experimental... Read more »
Exonics Therapeutics, one of the players in an emerging race to use gene therapy or gene editing techniques to treat Duchenne muscular dystrophy, has just landed a big round of funding... Read more »
The FDA has cleared Cellectis to resume testing an experimental “off the shelf” type of cell therapy, so long as it follows a new set of measures meant to quell the... Read more »
Two biotechs, Spero Therapeutics and Allena Therapeutics, are headed for the Nasdaq this morning at valuations they’d been aiming for. Their stock offerings are the latest sign of the health of... Read more »
CRISPR-Cas9 makes headlines as a gene editing tool for potential therapies, but pharma and biotech are also using it to as a tool to discover new drugs. A high-powered startup, KSQ... Read more »
Genocea Biosciences was able to go from startup to publicly traded company, in part, because of the early progress it made developing an experimental vaccine for genital herpes. Yet the... Read more »
Pfizer is testing out a new biotech experiment this morning. It has taken four drug compounds gathering dust on its shelves, and funneled them into a new startup, SpringWorks Therapeutics, that... Read more »
[Updated with comments at 9:49 am ET, see below] For the first time ever, a medicine using RNA interference, a method of muting a gene before it can make... Read more »
Can the life sciences industry finally begin to efficiently and systematically exploit the potential treasure trove of drugs hidden in fungi? It seems promising, thanks to cheaper DNA sequencing technologies, artificial... Read more »
Flagship Pioneering has been as active as any venture firm at funneling its investment dollars into microbiome drug developers. It’s putting some more of that cash to work as of this... Read more »
An option-to-buy deal, when one company agrees to buy another on prearranged terms after a series of milestones are met, doesn’t always lead to an acquisition. Sometimes, as with a 2016... Read more »
Moderna Therapeutics, the high-flying private company with a $1 billion war chest, is reversing course. Three years ago, it decided to hatch startups as wholly-owned subsidiaries, all working on different aspects... Read more »
Epidermolysis bullosa is a rare, debilitating skin disease with no approved treatments, and unfortunately, that isn’t going to change anytime soon. Amicus Therapeutics reports this morning that an experimental drug it... Read more »
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.